Digest Network Come funziona
Network
/
Società
Im
Non verificato

ImmunityBio, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

51 comunicati stampa

Guarda tutti i comunicati
23/01/2026
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
16/01/2026
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
16/01/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
15/01/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
14/01/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
Industria
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
13/01/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Mercato del lavoro
Eventi
Industria
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
29/12/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Mercato del lavoro
Eventi
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
16/12/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
13/11/2025
Analisi di mercato
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0